Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 3/20 | 0.72 |
| ▸ | MAP3K5 | Q99683 | 13/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485756 | 0.91 | MAP3K5 (0.61) | CLK2MAP3K5RETCDK2GSK3B | |
| SCHEMBL3486384 | 0.89 | MAP3K5 (0.63) | CLK2MAP3K5RETCDK2GSK3B | |
| SCHEMBL30789750 | 0.84 | CLK2 (1.00) | CLK2MAP3K5MCHR1RETCDK2 | |
| SCHEMBL3487041 | 0.83 | MAP3K5 (0.71) | CLK2MAP3K5RETCDK2GSK3B | |
| SCHEMBL3486423 | 0.83 | CLK2 (0.70) | CLK2MAP3K5MCHR1RETCDK2 | |
| SCHEMBL3486408 | 0.82 | CLK2 (0.65) | CLK2MAP3K5MCHR1RETCDK2 | |
| SCHEMBL3485764 | 0.81 | CLK2 (0.68) | CLK2MAP3K5MCHR1RETCDK2 | |
| SCHEMBL3487163 | 0.81 | CLK2 (0.67) | CLK2MAP3K5MCHR1RETCDK2 | |
| SCHEMBL3486279 | 0.80 | CLK2 (0.66) | CLK2MAP3K5MCHR1RETCDK2 | |
| SCHEMBL3486200 | 0.79 | CLK2 (0.68) | CLK2MAP3K5MCHR1RETCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | CLK2 2521/4885MAP3K5 42/4885MCHR1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.